胆汁酸-微生态轴在肝硬化进展中的调节作用

摘要/Abstract

摘要： 肝硬化是一种最常见的全球慢性肝病,微生物-胆汁酸轴和宿主之间的联系在肝硬化的发病机制中起着关键作用。二者与疾病之间的联系不仅可被用于诊断肝硬化,还可积极用于肝硬化的治疗。大量研究和综述描述了胆汁酸在肝硬化发病机制中的关键作用,肠道微生物群特征组在健康人群和肝硬化患者之间变化,促进次级胆汁酸的转化,对胆汁酸多样性起决定作用,并通过胆汁酸-微生态轴影响肝硬化病程进展。本文回顾了胆汁酸合成代谢、肝硬化及肝性脑病疾病进展中的肠道微生物特征组变化关系,以期为肝硬化的临床治疗及并发症处理提供新的治疗思路。

关键词: 肠道微生物, 胆汁酸, 肝硬化, 肝性脑病, 胆汁酸-微生态轴

王海强, 郑淑丹, 石璠, 赵梅, 郑丽红. 胆汁酸-微生态轴在肝硬化进展中的调节作用[J]. 肝脏, 2023, 28(9): 1119-1122.

参考文献

[1] Shao JW, Ge TT, Chen SZ, et al. Role of bile acids in liver diseases mediated by the gut microbiome.World J Gastroenterol,2021,27(22):3010-3021.
[2] Simerrunner B,Traunner M, Reiberger T. Review article: therapeutic aspects of bile acid signalling in the gut-liver axis.Aliment Pharmacol Ther,2021,54(10):1243-1262.
[3] Xie A, JMai CT, Zhu YZ, et al. Bile acids as regulatory molecules and potential targets in metabolic diseases.Life Sci,2021,287:120152.
[4] Meadows V, Kennedy L, Kundu Det al. Bile acid receptor therapeutics effects on chronic liver diseases.Front Med,2020,7:15.
[5] Katafuchi T, Makishima M. Molecular basis of bile acid-FXR-FGF15/19 signaling axis.Int J Mol Sci,2022,23(11):6046.
[6] Chiang JYL, Ferrell JM. Bile acids as metabolic regulators and nutrient sensors.Annu Rev Nutr,2019,39:175-200.
[7] Tranah TH, Edwards LA, SchCnabl B, et al.Targeting the gut-liver-immune axis to treat cirrhosis.Gut,2021,70(5):982-994.
[8] Yang T, Khan GJ, Wu Z, et al. Bile acid homeostasis paradigm and its connotation with cholestatic liver diseases.Drug Discov Today,2019,24(1):112-128.
[9] Chiang JYL, Ferrell JM. Bile acid biology,pathophysiology,and therapeutics.Clinical liver disease,2020,15(3):91-94.
[10] Jia W,Xie G,Jia W.Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis.Nat Rev Gastroenterol Hepatol,2018,15(2):111-128.
[11] Stofan M, Guo GL. Bile acids and FXR: novel targets for liver diseases.Front Med,2020,7:544.
[12] Ratto D, Roda E, Romeo M, et al. The many ages of microbiome-gut-brain axis.Nutrients,2022,14(14):2937.
[13] Ikegami T, Honda A. Reciprocal interactions between bile acids and gut microbiota in human liver diseases.Hepatol Res,2018,48(1):15-27.
[14] Hrncir T, Hrnicrova L, Kverka M, et al. Gut microbiota and NAFLD: pathogenetic mechanisms, microbiota signatures, and therapeutic interventions.Microorganisms, 2021,9(5):957.
[15] Chen Z, Ruan J, Li D, et al. The role of intestinal bacteria and gut-brain axis in hepatic encephalopathy.Front Cell Infect Microbiol,2020,10:595759.
[16] Ganesan R, Jeong J-J, Kim DJ, et al. Recent trends of microbiota-based microbial metabolites metabolism in liver disease.Front Med,2022,9:841281.
[17] Hatton G, Shawcross DL. Is treating the gut microbiome the key to achieving better outcomes in cirrhosis?.Expert Rev Gastroenterol Hepatol,2019,13(1):1-2.
[18] Liu Y, Chen K, Li F, et al. Probiotic lactobacillus rhamnosus GG prevents liver fibrosis through inhibiting hepatic bile acid synthesis and enhancing bile acid excretion in mice.Hepatology,2020,71(6):2050-2066.
[19] Ridlon JM, Aives JM, Hylemon PB, et al. Cirrhosis, bile acids and gut microbiota: unraveling a complex relationship.Gut Microbes,2013,4(5):382-387.
[20] Sydor S, Best J, Messerschmidt I, et al. Altered microbiota diversity and bile acid signaling in cirrhotic and noncirrhotic NASH-HCC.Clin Transl Gastroenterol,2020,11(3):e00131.
[21] Kakiyama G, Hylemon PB, Zhou H, et al. Colonic inflammation and secondary bile acids in alcoholic cirrhosis.Am J Physiol Gastrointest Liver Physiol, 2014,306(11):G929-G937.
[22] Brandl K, Hartmann P, Jih LJ, et al. Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis.J Hepatol,2018,69(2):396-405.
[23] Li DK, Chaudhari SN, Lee Y, et al. Inhibition of microbial deconjugation of micellar bile acids protects against intestinal permeability and liver injury. Sci Adv,2022,8(34):eabo2794.
[24] Sorrentino G, Perino A, Yildiz E, et al. Bile acids signal via TGR5 to activate intestinal stem cells and epithelial regeneration.Gastroenterology,2020,159:956-968.
[25] Poland JC, Flynn CR. Bile acids, their receptors, and the gut microbiota. Physiology (Bethesda),2021,36(4):235-245.
[26] Demorrow S. Bile acids in hepatic encephalopathy.J Clin Exp Hepatol,2019,9(1):117-124.
[27] Arjunan A, Sah DK, Jung YD, et al. Hepatic encephalopathy and melatonin.Antioxidants (Basel),2022,11(5):837.
[28] Wang T, Li XJ, Qin LH, et al. Better detoxifying effect of ripe forsythiae fructus over green forsythiae fructus and the potential mechanisms involving bile acids metabolism and gut microbiota.Front Pharmacol,2022,13:987695.
[29] Xie G, Wang X, Jiang R, et al. Dysregulated bile acid signaling contributes to the neurological impairment in murine models of acute and chronic liver failure.EBioMedicine,2018,37:294-306.
[30] 李莉莉,谢瑞祺,王莉,等.肝硬化患者肠道微生物与生化指标的关联性.生物学杂志,2021,38(06):82-86.
[31] Bajaj JS, Heuman DM, Hylemon PB, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications.J Hepatol,2014,60(5):940-947.
[32] Won S-M, Oh KK, Gupta H, et al. The link between gut microbiota and hepatic encephalopathy.Int J Mol Sci,2022,23(16):8999.
[33] Gómez-Hurtado I, Santacruz A, Peiró G, et al. Gut microbiota dysbiosis is associated with inflammation and bacterial translocation in mice with CCl4-induced fibrosis.PLoS One,2011,6(7):e23037.
[34] Tranah TH, Edwards LA, Schnabl B, et al. Targeting the gut-liver-immune axis to treat cirrhosis.Gut,2021,70(5):982-994.
[35] Iebba V, Guerrieri F, Di Gregorio V, et al. Combining amplicon sequencing and metabolomics in cirrhotic patients highlights distinctive microbiota features involved in bacterial translocation, systemic inflammation and hepatic encephalopathy.Sci Rep,2018,8(1):8210.
[36] Bajaj JS, Gentili A, Wade JB, et al. Specific challenges in geriatric cirrhosis and hepatic encephalopathy.Clin Gastroenterol Hepatol,2022,20(8S):S20-S29.
[37] Yukawa-Muto Y, Kamiya T, Fujii H, et al. Distinct responsiveness to rifaximin in patients with hepatic encephalopathy depends on functional gut microbial species.Hepatol Commun,2022,6(8):2090-2104.
[38] Dalal R, McGee RG, Riordan SM, et al. Probiotics for people with hepatic encephalopathy.Cochrane Database Syst Rev,2017,2:CD008716.
[39] Liu J, Xu Y, Jiang B. Novel insights into pathogenesis and therapeutic strategies of hepatic encephalopathy, from the gut microbiota perspective.Front Cell Infect Microbiol,2021,11:586427.
[40] Jung JH, Kim S-E, Suk KT, et al. Gut microbiota-modulating agents in alcoholic liver disease: links between host metabolism and gut microbiota.Front Med (Lausanne),2022,9:913842.
[41] Sung CM, Lin YF, Chen KF, et al. Predicting clinical outcomes of cirrhosis patients with hepatic encephalopathy from the fecal microbiome.Cell Mol Gastroenterol Hepatol,2019,8(2):301-318.
[42] 林镛,颜耿杰,冯逢,等.基于16SrRNA技术探讨轻微型肝性脑病患者肠道菌群的变化特征.中西医结合肝病杂志,2022,32(3):201-206.